Literature DB >> 17001802

Hepatitis C virus therapies.

Richard E T Smith.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001802     DOI: 10.1038/nrd2134

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

1.  Evaluation of operational chronic infection endpoints for HCV vaccine trials.

Authors:  Minhee Kang; Uwe Nicolay
Journal:  Contemp Clin Trials       Date:  2008-04-09       Impact factor: 2.226

2.  GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.

Authors:  Pei-Bin Zhai; Jie Qing; Ben Li; Lin-Qi Zhang; Lan Ma; Li Chen
Journal:  Acta Pharmacol Sin       Date:  2018-06-21       Impact factor: 6.150

3.  N-substituted benzyl matrinic acid derivatives inhibit hepatitis C virus (HCV) replication through down-regulating host heat-stress cognate 70 (Hsc70) expression.

Authors:  Na-Na Du; Zong-Gen Peng; Chong-Wen Bi; Sheng Tang; Ying-Hong Li; Jian-Rui Li; Yan-Ping Zhu; Jing-Pu Zhang; Yan-Xiang Wang; Jian-Dong Jiang; Dan-Qing Song
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

4.  Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors.

Authors:  Beilei Lei; Juan Du; Shuyan Li; Huanxiang Liu; Yueying Ren; Xiaojun Yao
Journal:  J Comput Aided Mol Des       Date:  2008-08-21       Impact factor: 3.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.